Overview

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2020-08-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.

Phase:

Phase 3

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborators:

Genzyme, a Sanofi Company
National Cancer Institute (NCI)

Treatments:

Clofarabine
Cytarabine
Daunorubicin
Etoposide
Etoposide phosphate